Special Issue "Histone Modification Enzymes and Long Noncoding RNAs in Cancer"
Deadline for manuscript submissions: closed (12 November 2018)
Prof. Tao Liu
Dr. Jenny Wang
Post-translational histone modifications are regulated by histone modification enzymes, which can be divided into writers, erasers, and readers. Histone writers include histone acetyltransferases and methyltransferases, while histone deacetylases and demethylases are among erasers. Histone readers, such as BET (bromodomain and extra-terminal domain) protein family and SWI/SNF (switch/sucrose non-fermentable) complex, recognize histone acetylation and methylation. Through modulating gene transcription, histone modification enzymes significantly down-regulate tumor suppressor gene and up-regulate oncogene expression, and thereby play critical roles in tumor initiation and progression. Small molecule inhibitors of the aberrant histone modifications have been developed, and some of them, such as the histone deacetylase inhibitors vorinostat and panobinostat, have been approved for cancer therapy in patients. More recently, histone methyltransferase inhibitors, such as the DOT1L inhibitor EPZ-5676 and the EZH2 inhibitor Tazemetostat, histone demethylase inhibitors, such as the LSD1 inhibitors GSK2879552 and RG6016, and the BET bromodomain inhibitors OTX015 and GSK525762 have entered various phases of clinical trials in cancer patients.
While well-known to form protein complexes with transcriptional activators, repressors, co-activators and co-repressors, histone modification enzymes have recently been demonstrated to be recruited by long noncoding RNAs (lncRNAs) to target gene promoters and enhancers, and lncRNAs are emerging as critical regulators of gene transcription, tumor initiation and progression. Unlike protein-coding genes, the majority of lncRNAs are expressed in tissue, cell lineage and developmental stage-dependent manners. This unique expression pattern makes lncRNAs better cancer biomarkers and ideal therapeutic targets. Development of inhibitors which block the interaction between lncRNAs and their partner histone modification enzymes is likely to provide novel cancer treatments with better therapeutic index.
In this Special Issue, we welcome reviews, new methodologies and original articles covering histone modification enzymes and lncRNAs.
Prof. Tao Liu
Dr. Jenny Wang
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Histone modification enzymes
- Histone modification enzyme inhibitors
- Gene transcription
- Long noncoding RNA
- Cancer therapy